Find information on Tardive Dyskinesia diagnosis, including clinical documentation, medical coding, ICD-10 codes (G24.01, F98.1), treatment, and management. Learn about symptoms, assessment, and care for TD. Resources for healthcare professionals, including coding guidelines, best practices, and clinical support for Tardive Dyskinesia.
Also known as
Drug-induced tardive dyskinesia
Tardive dyskinesia caused by medication use.
Tourette's syndrome
A neurological disorder with tics; can be misdiagnosed as TD.
Abnormal involuntary movements
Encompasses various movement disorders including possible TD symptoms.
Other extrapyramidal and movement disorders
Includes less specific movement disorders that may overlap with TD.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the dyskinesia drug-induced?
When to use each related code
| Description |
|---|
| Involuntary movements after long-term antipsychotic use. |
| Drug-induced parkinsonism from dopamine blockers. |
| Neuroleptic malignant syndrome, a rare, life-threatening reaction. |
Coding TD without specifying drug-induced or other causes leads to inaccurate reporting and potential payment errors. Use G24.4 if drug-induced, other codes if not.
Lack of clear TD documentation by clinicians can cause undercoding. CDI specialists should query for symptoms like involuntary movements to ensure proper coding.
Failure to document causative neuroleptic medications can hinder accurate TD attribution. Proper medication coding helps establish the drug-induced link for G24.4.
Patient presents with signs and symptoms consistent with tardive dyskinesia (TD). The patient exhibits involuntary, repetitive movements, primarily affecting the orofacial region, including lip smacking, chewing motions, tongue thrusting, and facial grimacing. These extrapyramidal symptoms (EPS) emerged following prolonged exposure to antipsychotic medication, specifically [medication name and dosage]. The patient's medical history includes [list relevant medical history, including duration of antipsychotic use]. AIMS (Abnormal Involuntary Movement Scale) examination score of [score] was recorded, indicating [severity - e.g., mild, moderate, severe] TD. Differential diagnoses considered included Huntington's disease, Tourette's syndrome, and other drug-induced movement disorders. These were ruled out based on clinical presentation, history, and neurological examination. The diagnosis of tardive dyskinesia is supported by the temporal relationship between antipsychotic use and the onset of symptoms, the characteristic nature of the involuntary movements, and the absence of alternative explanations. Treatment plan includes consideration of [e.g., valbenazine, deutetrabenazine, or discontinuationreduction of the offending agent if clinically feasible]. Patient education regarding tardive dyskinesia, its potential long-term implications, and medication management strategies was provided. Follow-up appointment scheduled in [ timeframe] to monitor symptom progression and treatment response. ICD-10 code G24.4 and relevant CPT codes for evaluation and management will be documented for billing and coding purposes.